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Innovations
Zyomyx
Protein Chips: Protein Chemistry Comes to the Surface
pelling; the question on the minds tools, it is important to look at the
materials through ‘biomolecularof many, however, is whether this
glasses’.”theory can be made a practical real-
High-throughput approaches have
had an important impact on biologi-
cal research over the past decade,
particularly in drug discovery. Phar- Some of the earlier work on engi-ity. According to Zyomyx chief exec-
maceutical companies routinely em- neering DNA microarrays took placeutive Larry Cohen, the answer is an
ploy massively parallel formats in at Stanford University, with labsunequivocal yes.
their attempts to screen large librar- such as Pat Brown’s and Ron Davis’The reality is that arraying pro-
ies of synthetic or natural small mol- at the forefront. It was there thatteins to a solid surface in an active
ecules for new drug leads—the im- Wagner met Zyomyx cofounderform is neither a simple nor straight-
petus being both efficiency and Steffen Nock, at the time a post docforward task. In fact, there really is
economy of scale. The advent of in the laboratory of Jim Spudich inno standard chemistry for affixing
DNA chip technology in the mid-90s the Department of Biochemistry.proteins to a solid surface, and there
represented an extension of ultra- Wagner was a biophysicist special-will likely never be one. Proteins
high-throughput science to gene ex- ized in surface chemistry and was ahave much greater variation in struc-
pression profiling and coincided Humboldt fellow also working withture and function than nucleic acids
nicely with the sequencing of the hu- Spudich. Nock was trained as a tra-and are also much less stable than
man and many other genomes. Not ditional biochemist and molecularDNA. The delicate three-dimen-
only were the sequences available, biologist and knew how to producesional structure of proteins is di-
but the solid-state technology was high-quality recombinant protein.rectly linked to their function and can
there, borrowed from the semicon- They were part of a multidisciplinary
ductor and high-tech industries— group studying ways of affixing, ar-
from silicon chips to ink-jet printing ranging, and imaging active protein
“The fundamental chal-to photolithography. Big pharma molecules on solid surfaces. The goal
of their project was to study how mo-was one of the early adopters of the lenge in developing pro-
nascent technology, as the new lecular motor proteins moved on sur-tein chips derives from the
tools promised to facilitate the faces. “Needless to say, surface
interplay between proteinsearch for expression markers and chemistry and how these motor pro-
teins attached to the solid interfacedrug targets associated with cancer structure and the molecu-
and other disease. were essential to the outcome oflar complexities of surface
High-throughput science paired these experiments,” adds Wagner.
chemistry. When devel-up with protein science in the late The year was 1998, and Silicon
Valley was in the grips of the high90s, and the field of “proteomics” oping surface-based ana-
was born. Falling under the proteo- tech and dot-com craze. DNA chiplytical tools, it is impor-
mics banner were protein expres- technology was at its peak, and the
tant to look at the materi-sion profiling, functional genomics, industrialization of biology was in
vogue. According to Nock, who, likeand the study of protein-protein in- als through ‘biomolecular
teractions. The new field needed Wagner, hailed from Europe, the at-glasses’.” –Peter Wagner,new tools, and according to Zyomyx mosphere at Stanford was dramati-
Zyomyx founder and CTO(www.zyomyx.com), a small biotech cally different from the stodgy, aca-
company in the Bay area, protein demic nature of European science
chips represent the next logical step at that time. Many of the faculty at
be severely affected by the naturein the evolution of massively parallel Stanford had either started biotech
of the surface during the immobiliza-screening technology. Proteins are companies or were advising them.
tion process and thereafter. Dena-generally the key players in disease, “Venture capitalists were literally
turation is a particular problem whenthey reason—so why not measure roaming the halls looking for invest-
proteins find themselves at a solid-them directly? DNA chips might tell ment opportunities,” says Nock, “we
liquid interface, as on the surface ofyou which genes are on and which saw the buzz over DNA chips and it
a silicon chip. As Zyomyx founderare off, but mRNA levels do not nec- occurred to us that our work could
and current CTO Peter Wagner ex-essarily correlate with protein levels be of interest to both the investor
plains, “the fundamental challengein a cell. Moreover, DNA chips can- and pharmaceutical communities.”
in developing protein chips derivesnot tell you whether the correspond- Although the business would be
from the interplay between proteining proteins are active, scheduled born out of Nock and Wagner’s col-
structure and the molecular com-for degradation, or even in the right laboration at Stanford, much of the
plexities of surface chemistry. Whenplace in the cell. In theory at least, technology underlying Zymoyx’s vi-
sion had its origins at the Swiss Fed-the case for the protein chip is com- developing surface-based analytical
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eral Institute of Technology in Zurich nostics for medical and pharmaceu- point for the capture molecules of
choice, creating a very specific bio-twelve years earlier. There, Wagner tical applications. These first chips
are designed to measure chemo-had put together a scientifically di- reactivity for the cognate analyte.
These capture molecules could beverse, multidisciplinary research kines, the molecular messengers of
the immune system. Part of the logicprogram that merged nanotechnol- either streptavidin-linked antibodies
or Fab fragments. Importantly, Zyo-ogy with biology. The group was behind creating a chemokine chip
was to exploit the advantages thatdedicated to the study of protein myx has inked supply and collabora-
tion agreements giving them accessfunction at the molecular level, and the protein chip format provides
over a DNA chip for certain applica-surface-based analytical tools and to vast antibody libraries from three
of the larger players in the area, BDmethods of protein immobilization tions. Chemokines are secreted pro-
teins that localize to very specificwere instrumental for these studies. Biosciences, Cambridge Antibody
Technology, and Dyax Corp.“Few biologists appreciated the regions of the immune system, often
quite distant to the cell type in whichcomplexity of surface chemistries, The raised pillars are only 50 mi-
crons in diameter, fitting about a mil-and few surface chemists appreci- their mRNA was produced. DNA
chips are simply not suited to suchated the complexity of protein struc- lion antibody molecules in each chip
feature. According to Cohen, whotures. The key was to get these soluble analytes.
As with DNA chips, the startinggroups working with each other,” joined Zyomyx in 1999, 90% of those
molecules must be active and ori-explains Wagner. The outcome of point of the BioChip is a silicon wa-
fer. Unlike DNA arrays, the surfacethis work was key to the new tools ented properly to allow the neces-
sary sensitivity for the assay. GettingNock and Wagner wanted to create is rendered hydrophilic rather than
hydrophobic. For DNA arrays, hy-at Zyomyx. almost a million protein molecules
onto the surface without denaturingThose new tools were chip- drophobicity helps limit feature size
so as to produce chips of the highestbased arrays of recombinant protein them is no easy task. To achieve this,
Zymoyx has developed a proprietaryto facilitate the study of protein ex- density. For protein chips, sensitivity
is the key, rather than density. “Withpression and function. The original technique for parallel printing. The
design of the chip ensures that theidea was to create functional assays protein chips, there has been a para-
digm shift from density to qualityfor high-throughput drug discov- capture molecules remain in solu-
tion, preventing drying out. A mereery—to facilitate screening of a and accuracy of the individual data
point,” explains Nock, “and this cre-panel of kinases, for example, ten microliters of blood is used for
the chemokine assay, which is “pro-against different substrates. Armed ates a whole different set of analyti-
cal and process tools.” The waferwith a PowerPoint presentation and cessed” by exposure to a second
set of anti-chemokine antibodiesdesign specs for a prototype chip, is subjected to photolithography to
create raised pillars on the surfaceNock and Wagner went on the road and a fluorescence-based detec-
tion system.to sell their idea to the community. of the chip that are coated with an
inorganic material, such as titaniumThey spent about a year talking to The logic behind the collabora-
tion with Specialty was to get theinvestors and big pharma, gathering oxide. This creates a negatively
charged surface onto which a layerintelligence on the potential interest chips into the hands of those with
experience in evaluating assays forin their “protein chip.” What they of organic polymer is laid to create
an interface suitable for the bindinglearned was that what people really reference laboratory uses. Clinical
diagnostics is a key market the com-wanted to do was expression profil- and orientation of the capture mole-
cule of choice.ing, similar to what DNA chips were pany is targeting, and optimization
and standardization of the chips willdoing for mRNA expression. Although the detailed specifics of
the manufacture of the chemokineThey secured their first million be crucial for the eventual adapta-
tion of the chips for use in clinicalfrom Skyline Ventures in late ’98, fol- chips are proprietary, Zyomyx did
publish a paper last year (Ruiz-lowed by an additional eight million trials and preclinical studies. In fact,
as this article went to press, Zyomyxthe next year. The cash allowed Talyor et al., 2001, Proc. Natl. Acad.
Sci. USA 98, 852–857) describing athem to incorporate and recruit staff, announced a strategic alliance with
Partners HealthCare Boston to pro-many drawn from the same Zurich prototype chip design. In that work,
the authors used the organic poly-group of which Wagner had been a vide the tools for a core protein pro-
filing facility at Harvard University’spart years earlier. Zyomyx now has mer poly(L-lysine)-grafted-poly(eth-
ylene glycol), PLL-g-PEG, with theabout $64 million venture funding in teaching hospitals. “Comparing pro-
teins that are expressed in diseasedthe bank and receives payments PEG moiety derivatized with a biotin
molecule. The positively chargedfrom a strategic collaboration with versus normal human samples
allows researchers to identify andthe Japanese biotech firm Fujirebio, PLL forms an ordered monolayer on
the negatively charged surface ofInc. Importantly, they hope to have validate patterns of biomarkers that
define specific diseases,” explainstheir chips in tests with six groups the chip, such that the PEG moiety
points upward into the aqueous so-worldwide by the end of 2002. Cohen, “Diagnostic tests based on
these biomarkers will be importantIn fact, Zyomyx delivered its first lution on the chip. PEG compounds
resist nonspecific protein binding,Protein Profiling Biochip in May of tools to enhance clinical trials de-
sign and ultimately to identify the2002 to its first “early access” col- significantly reducing the adsorp-
tion of proteins from the protein mix-laborator, Specialty Laboratories, most effective therapy for the
patient.”Inc., a world leader in the develop- ture being assayed. The biotin mole-
cule provides a specific attachmentment and validation of clinical diag- A key selling point to their chips,
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according to Cohen, is the fact that
Zyomyx is not just providing chips,
but a complete system. “This makes
us unique in the protein chip market-
place at present,” he adds. The fluo-
rescence-based chip reader was
codeveloped with Axon Instru-
ments, a well-established producer
of DNA chip readers. A fluidics work-
station can process 12 chips at a
time, in about 1–2 hours. Software
is also provided for data capture and
analysis. Then, of course, there are
the chips themselves and the neces-
sary reagents.
Although much of their future
hinges upon the success of the Pro-
tein Profiling Biochip, Zyomyx is ac-
tively working on several related but
distinct products with several part-
ners. Canadian testing company MDS
is working with them on a protein in-
teraction assay—a sort of solid-state
two-hybrid assay. Another product
under development is a chip to mea-
sure the activity of arrayed ion chan-
nels—interesting drug targets, but
particularly difficult to work with due
to their membrane localization. Un-
like the DNA chip market, which is
dominated by a couple of formats
and major manufacturers, the diver-
sity of protein structure seems likely
to give rise to a diversity of protein
chip formats and a more diverse
marketplace. Although the number
of assays on the chemokine chip is
only 25, higher-density formats—
perhaps into the 1000s—are under
development. Alternative detection
systems, such as time-of-flight mass
spectrometry, are also in the works.
As the protein chip market has been
estimated by some to eventually hit
a billion dollars annually, the pay-off
could be dramatic. As the efforts of
Zyomyx have shown, understanding
that market and the potential de-
mand will be key to realizing these
pay-offs.
Chemistry & Biology invites your
comments on this topic. Please
write to the editors at chembiol@-
cell.com.
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